<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53218">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413372</url>
  </required_header>
  <id_info>
    <org_study_id>MB130-045</org_study_id>
    <nct_id>NCT02413372</nct_id>
  </id_info>
  <brief_title>A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether BMS-986036 is effective in the treatment
      of subjects with Non-alcoholic Steatohepatitis (NASH).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent hepatic fat fraction (%) by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>From screening/baseline to week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by adverse events (AEs)</measure>
    <time_frame>From screening/baseline, subsequent days after, upto week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by clinical laboratory tests</measure>
    <time_frame>From screening/baseline, subsequent days after, upto week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by vital signs</measure>
    <time_frame>From screening/baseline, subsequent days after, upto week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by electrocardiograms</measure>
    <time_frame>From screening/baseline, subsequent days after, upto week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by physical examinations</measure>
    <time_frame>From screening/baseline, subsequent days after, upto week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, as measured by bone mineral density</measure>
    <time_frame>From screening/baseline, subsequent days after, upto week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMS-986036 observed concentration by Ctrough</measure>
    <time_frame>From Day 1 to Day 142</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-BMS-986036 antibodies</measure>
    <time_frame>From Day 1 to Day 142</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Treatment Group A: BMS-986036</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as specified on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B: BMS-986036</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as specified on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group C: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered as specified on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group D:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as specified on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group E:</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered as specified on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986036</intervention_name>
    <arm_group_label>Treatment Group A: BMS-986036</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986036</intervention_name>
    <arm_group_label>Treatment Group B: BMS-986036</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Treatment Group C: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986036</intervention_name>
    <arm_group_label>Treatment Group D:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Treatment Group E:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male or female between 21 and 75 years old

          -  Body Mass Index (BMI) of 25 or more

        Exclusion Criteria:

          -  Chronic Liver disease other than NASH

          -  Uncontrolled diabetes

          -  Any major surgery within 6 weeks of screening

          -  Unable to self-administer under the skin injections

          -  Any bone trauma, fracture or bone surgery within 8 weeks of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health - University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of North Carolina At Chapel Hill School Of Med</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upmc Center For Liver Diseases</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research Pllc</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute, Llc</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi St. Luke'S Health Baylor College Of Medicine Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive And Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>April 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First Line Therapy</keyword>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
